4//SEC Filing
Harmon Cyrus 4
Accession 0001415889-24-029028
CIK 0001750284other
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 7:56 PM ET
Size
12.1 KB
Accession
0001415889-24-029028
Insider Transaction Report
Form 4
Harmon Cyrus
Director
Transactions
- Sale
Common Stock
2024-12-11$9.39/sh−179$1,681→ 764,140 total - Sale
Common Stock
2024-12-10$9.37/sh−8,256$77,359→ 772,277 total - Award
Common Stock
2024-12-09+29,250→ 780,533 total - Sale
Common Stock
2024-12-11$8.66/sh−7,958$68,916→ 764,319 total
Holdings
- 122,028(indirect: See Footnote)
Common Stock
Footnotes (6)
- [F1]On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 45,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria.
- [F2]The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F3]The weighted average sale price for the transaction reported was $9.37, and the range of prices was between $8.89 and $9.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F6]The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.
Documents
Issuer
Olema Pharmaceuticals, Inc.
CIK 0001750284
Entity typeother
Related Parties
1- filerCIK 0001831410
Filing Metadata
- Form type
- 4
- Filed
- Dec 10, 7:00 PM ET
- Accepted
- Dec 11, 7:56 PM ET
- Size
- 12.1 KB